Who founded Addition Therapeutics?

Addition Therapeutics was founded by Kathleen Collins in 2021.

Who are Addition Therapeutics's investors?

Addition Therapeutics's investors include BEVC, Pivotal Life Sciences, SR One Capital Management, Abingworth, Osage University Partners.

How much funding has Addition Therapeutics raised?

Addition Therapeutics has disclosed $128M raised across 2 rounds.

Where is Addition Therapeutics headquartered?

Addition Therapeutics is headquartered in South San Francisco, US.

Addition Therapeutics

South San Francisco, US · Founded 2021 · 69 employees on LinkedIn · 7 known investors

Find your way into Addition Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

449 people can intro you to Lawrence

Ask Graham Mills to introduce you to Lawrence Kong

You →Graham · together at Addition Therapeutics →Lawrence

85 people can intro you to Francine

Ask Jamie Chen to introduce you to Francine Gregoire

You →Jamie · together at Metabolex →Francine

Your email: who you already know at Addition Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Addition Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team. Its work centers on drug discovery and portfolio development in the life sciences.

Biotech Healthtech

Founders & leadership

Addition Therapeutics was founded in 2021 by Kathleen Collins.

Kathleen CollinsFounder

Lawrence Kong Executive Director, IP & Legal; Corporate SecretaryLawrence Kong held positions at Amgen and DuPont, as well as at law firms Morrison & Foerster and Wilson Sonsini, where he developed expertise in intellectual property, patents, and project management. He serves as Corporate Secretary at Addition Therapeutics, a biotechnology company focused on drug discovery and portfolio development.

Ron ParkPresident & CEO

Francine Gregoire Chief Scientific OfficerFrancine Gregoire holds a Ph.D. in Cell Biology and brings over 20 years of post-doctoral research experience in metabolic diseases, with deep expertise in drug discovery processes from target identification through clinical development.

Priya ParameswaranChief Business Officer

Board

Jayson Punwani Board directorManaging Director, Head of Venture at Abingworth

Peter Bisgaard Board directorManaging Director at Pivotal Life Sciences

Jennifer LeeBoard director

Laetitia Schwab Board MemberPrincipal at SR One Capital Management

Matthew Patterson Chairman of the BoardVenture Partner - US Investments at SR One Capital Management

Investors · 7

BEVClisted by BEVCSan Francisco

How we know: BEVC's portfolio page · pulse2.com · Not right? Tell us

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco

How we know: Pivotal Life Sciences's portfolio page · a partner's Signal profile · pulse2.com · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · board seat on SEC Form D · Not right? Tell us

AbingworthreportedLondon · $15M – $30M

How we know: a partner's Signal profile · pulse2.com · Not right? Tell us

Osage University PartnersreportedBala Cynwyd

How we know: pulse2.com · Not right? Tell us

Also in the syndicate · 2

Gates FoundationSR One

Funding

SEC filings, press & company announcements

$128M disclosed across 2 rounds · 2025

$100MraisedDec 2025 · 5 sources
Abingworth, BEVC, Gates Foundation, Osage University Partners, Pivotal Life Sciences, SR One
Source ↗

▶$28MraisedDec 2025 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kathleen CollinsDirector
Jayson PunwaniDirector
Matthew PattersonDirector
Peter BisgaardDirector
Lawrence KongExecutive Officer
Jennifer LeeDirector
Laetitia SchwabDirector
Ronald ParkExecutive Officer, Director

Offering amount: $28M
Amount sold: $28M
First sale: Dec 2025
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseasesfinance.yahoo.com · Dec 2025

Addition Therapeutics Raises $100M in Fundingfinsmes.com · Dec 2025

Frequently asked questions

What does Addition Therapeutics do?: Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team. Its work centers on drug discovery and portfolio development in the life sciences.
Who founded Addition Therapeutics?: Addition Therapeutics was founded by Kathleen Collins in 2021.
Who are Addition Therapeutics's investors?: Addition Therapeutics's investors include BEVC, Pivotal Life Sciences, SR One Capital Management, Abingworth, Osage University Partners.
How much funding has Addition Therapeutics raised?: Addition Therapeutics has disclosed $128M raised across 2 rounds.
Where is Addition Therapeutics headquartered?: Addition Therapeutics is headquartered in South San Francisco, US.